Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Cohort-design, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

NCT07207369 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07207369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07207369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Cohort-design, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Recruiting
Start date
October 24, 2025
Completion date
November 30, 2029
Enrollment
395 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acne scars